patent.fyi
Applications  /  US 2026/0355259
United States Patent Application Publication

US 2026/0355259 A1

Published
Nov 12, 2026
Filed
Jun 17, 2026
Earliest date on the face
Jan 9, 2024
Classification
A61K 35/616
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Small molecule calcineurin inhibition

What ifWhat if a topical ointment used a small-molecule calcineurin inhibitor as its active ingredient?
Claim language“extracellular vesicle (EV) as an active ingredient”

An ointment base distributes the inhibitor across affected skin. In T cells, the inhibitor binds an intracellular binding protein, and the resulting complex inhibits calcineurin and reduces transcription of inflammatory cytokines.

1.1Antibody blockade of cytokine signaling

What ifWhat if an injected monoclonal antibody blocked cytokine signaling through a shared receptor subunit?
Claim language“extracellular vesicle (EV) as an active ingredient”

A buffered aqueous injection delivers an antibody against the alpha subunit of the interleukin-4 receptor. Antibody binding inhibits signaling by interleukin-4 and interleukin-13, reducing type 2 inflammation.

1.1Topical phosphodiesterase inhibition

What ifWhat if a topical ointment used a small-molecule phosphodiesterase-4 inhibitor as its active ingredient?
Claim language“extracellular vesicle (EV) as an active ingredient”

The ointment delivers the inhibitor to affected skin. Inhibition of phosphodiesterase-4 slows cyclic AMP breakdown in inflammatory cells and reduces the release of inflammatory mediators.

1.1Topical glucocorticoid receptor activation

What ifWhat if a topical cream used a corticosteroid to suppress inflammation in affected skin?
Claim language“extracellular vesicle (EV) as an active ingredient”

An oil-in-water cream distributes the corticosteroid over lesions. The corticosteroid enters skin cells and binds the glucocorticoid receptor, changing gene expression and reducing production of inflammatory mediators.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Topical gel with synthetic liposomes

Synthetic phosphatidylcholine and cholesterol liposomes carrying niacinamide replace the sea cucumber extracellular vesicles in a topical formulation. The liposomes form when an aqueous niacinamide solution hydrates a dry lipid film, and size-exclusion chromatography separates the liposomes from unencapsulated niacinamide. A hydroxyethylcellulose gel holds the liposome dispersion against the application surface.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2017/0087087 A1
Published
Mar 30, 2017
Filed
Sep 28, 2016
Class
A61K 9/1075
Document BUS 2018/0296606 A1
Published
Oct 18, 2018
Filed
May 1, 2018
Class
A61K 35/28
Claim 1
Document A
Document B
1.1a Stichopus japonicus-derived extracellular vesicle (EV) as an active ingredient.
For example, the disclosed extracellular vesicles may be used for delivering a therapeutic agent such as cargo RNA to a target cell, where the methods include contacting the target cell with the disclosed extracellular vesicles.
A · US 2017/0087087 A1 · ¶ 49
In one aspect, the present disclosure provides a method of treating (including preventing) pulmonary hypertension, comprising administering to a subject in need thereof isolated extracellular vesicles or exosomes obtained from mesenchymal stromal cells, wherein the isolated extracellular vesicles or exosomes comprise extracellular vesicles or exosomes having increased expression of one or more expression products selected from the group consisting of (a) genes in the glycolys
B · US 2018/0296606 A1 · ¶ 5

An empty cell means only that no passage was reproduced there.

Statements in these documents
This method is novel in that it is the first to acknowledge and address the widespread problem of cleavage of targeting ligands from the luminal terminus extra of integral exosome membrane proteins during exosome biogenesis.
A · US 2017/0087087 A1 · ¶ 4
This targeting system can be used for engineering exosomes as targeted gene therapy or drug delivery vehicles in vivo, which could be applied to a wide variety of cell types and diseases.
A · US 2017/0087087 A1 · ¶ 4
The present application relates to methods of isolating potent extracellular vesicles, including exosomes, and the use of extracellular vesicles or exosomes in treatment of pulmonary hypertension, including pulmonary arterial hypertension (PAH), and conditions and diseases associated with mitochondrial dysfunction.
B · US 2018/0296606 A1 · ¶ 2
Thus, a need exists to develop improved therapeutic compositions and methods for treating pulmonary hypertension, such as by targeting mitochondrial function.
B · US 2018/0296606 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355259 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355259/, SHA-256 e4cd1598e9fc1ed69454e88c490e66a7645feac4230492c7c0e49c08d0a93287
First published
Permanent addresshttps://patent.fyi/US20260355259/
Content fingerprint (SHA-256)e4cd1598e9fc1ed69454e88c490e66a7645feac4230492c7c0e49c08d0a93287
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi